Response, complications and risk of leukemic transformation of phosphorus-32 p treatment in philadelphia-negative chronic myeloproliferative syndromes.

OBJECTIVE: Describe our experience in treatment with Phosphorus-32 P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation. MATERIAL AND METHODS: Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32 P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed. RESULTS: Of the 17 patients treated with 32 P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32 P administered was 116-951 MBq (median: 236 MBq). In 14 patients treated with Phosphorus-32 P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count < 400.000/mm3 in those diagnosed with Essential Thrombocythemia and a hematocrit < 45% in cases of Polycythemia Vera. The median follow-up of patients from the date of the first treatment of Phosphorus-32 P until study completion or death was 37 months (range: 5 - 230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and 1 case of mild thrombocytopenia. No leukemic transformation was identified. CONCLUSIONS: In our experience, treatment with Phosphorus-32 P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.

Localización atípica de metástasis de carcinoma de ovario detectada con 18F-FDG PET/TC / Atypical location of metastatic ovarian carcinoma detected by 18F-FDG PET/CT

No disponible

[Study of primary hyperparathyroidism by double-phase gammagraphy using Tc99m-MIBI: preoperative detection of pathological glands]. / Estudio del hiperparatiroidismo primario mediante gammagrafía en dos fases con 99mTc-MIBI: detección preoperatoria de las glándulas patológicas.

The preoperative use of imaging techniques to localize the diseased glands in primary hyperparathyroidism is still the subject of controversy. This paper assess the use of double-phase 99mTc-MIBI scintigraphy with that purpose. We examined 37 patients with primary hyperparathyroidism before surgical intervention. Two planar images 10 minutes and 3 hours after injection of 99mTc-MIBI were acquired. Final diagnosis was adenoma in 32 patients, 30 of whom had a positive scintigraphy (sensitivity 94%), with only two false negative results. In the other five patients, four with hyperplasia and one carcinoma, scintigraphy was also positive. Radioisotopic study was of particular interest in 5 patients who had undergone previous surgery; in one case, other diseased gland was located in the neck, and an ectopic adenoma was found in the remaining four cases. Two other ectopic lesions were also MIBI positive and, in these cases, scintigraphy was a direct indication for mediastinal surgery. There was no false positive results. We conclude that the high sensitivity and easy performance make double-phase 99mTc-MIBI scintigraphy the technique of choice for the preoperative localization of diseased glands in primary hyperparathyroidism, especially in cases of adenoma. Its use is of particular interest in adenomas with aberrant location and in patients who have undergone previous surgery.